{"id":63600,"date":"2024-12-11T10:49:46","date_gmt":"2024-12-11T09:49:46","guid":{"rendered":"https:\/\/lukasiewicz.gov.pl\/a-polish-game-changer-in-the-treatment-of-multiple-sclerosis\/"},"modified":"2025-01-22T10:26:29","modified_gmt":"2025-01-22T09:26:29","slug":"a-polish-game-changer-in-the-treatment-of-multiple-sclerosis","status":"publish","type":"post","link":"https:\/\/lukasiewicz.gov.pl\/en\/a-polish-game-changer-in-the-treatment-of-multiple-sclerosis\/","title":{"rendered":"A Polish “game changer” in the treatment of multiple sclerosis"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Ju\u017c wkr\u00f3tce chorzy na stwardnienie rozsiane otrzymaj\u0105 dost\u0119p do ta\u0144szych i skuteczniejszych lek\u00f3w. Opracowana w Polsce technologia produkcji tabletek zawieraj\u0105cych kladrybin\u0119 przyniesie prawdziwy prze\u0142om na rynku, zwi\u0119kszaj\u0105c dost\u0119p do skutecznego leczenia. <\/strong><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u0141ukasiewicz – Institute of Industrial Chemistry signed an agreement with the National Centre for Research and Development (NCRD) to start the project titled “Development of an innovative technology for the production of a medicinal product used in the treatment of multiple sclerosis”. The undertaking, which is worth PLN 38.8 million, will be co-financed with EU funds at the sum of PLN 20.4 million. <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t

\n\t\t\t\tWe want effective multiple sclerosis treatment to be available to every patient. A new, cheaper, effective drug will be developed in our laboratories. We will create it from scratch; starting with the synthesis of the active ingredient, through the development of the drug technology, we will carry out the entire scale-up process until we have a product ready for sale in pharmacies. By doing so, we will break the current market monopoly responsible for such high treatment costs. \t\t\t<\/p>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\tdr in\u017c. Ewa \u015amigiera, dyrektor \u0141ukasiewicz \u2013 IChP<\/cite>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/blockquote>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The scope of the project includes carrying out, a number of complementary research works in the areas of chemistry, physico-chemistry, analytical studies, studies of drug formulation technology with process scaling and the development of documentation required by pharmaceutical law to confirm the quality, efficacy and safety of a generic oral pill with cladribine API. Developing the drug will be based on the company’s own proprietary solutions, and the overarching goal of the project is to register a new multiple sclerosis treatment drug. One of the key research and technological problems will be to conduct a large pool of experiments with critical analysis of the results in order to obtain a stable formulation of the medicinal product under laboratory conditions and later in a scale-up process in a controlled area. <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t

\n\t\t\t\tOur advantage consists in the fact that we have many years of experience in the synthesis of active substances, including the production of cladribine. Our skills, backed by decades of experience, have been successfully applied in the development of further pharmaceutical manufacturing technologies, including the production of Biodribin\u00ae, a drug successfully used in oncology therapy. The same active substance can be used in tablets for the treatment of the high-functioning projective form of multiple sclerosis. This constitutes the aim of our project activities. \t\t\t<\/p>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\tWojciech Maszewski, dyrektor Departamentu Produkt\u00f3w Farmaceutycznych \u0141ukasiewicz \u2013 IChP<\/cite>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/blockquote>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u0141ukasiewicz – IChP is the only Polish manufacturer of the active substance cladribine, obtained on the basis of its own technology as well as know-how, and produced in its own laboratories. This makes the entire process independent of the changing external environment (e.g. external producers of active substances). <\/p>\n

Currently, there is only one oral formulation containing cladribine available on the market, which has patent protection for the drug form and dosage regimen. The lack of competition results in that the price of this drug is very high (up to several thousand zlotys per pill), making the availability of the product to patients significantly limited. The market launch of the medicinal product developed under the \u0141ukasiewicz – IChP project, used in the treatment of multiple sclerosis, will significantly shape this market segment. <\/p>\n

It is estimated that there are 2.8 million people with multiple sclerosis worldwide. According to the Ministry of Health, the number of patients in Poland in 2012 was 16.44\/10 000 of the population, and already twice as many in 2021. Developments in medicine and increased access to treatment have meant that the progression of the disease can be significantly slowed down and patients can lead almost completely normal and active lives. <\/p>\n

Stwardnienie rozsiane (SM) jest przewlek\u0142\u0105, nieuleczaln\u0105 chorob\u0105 o\u015brodkowego uk\u0142adu nerwowego. Jej bezpo\u015brednia przyczyna wci\u0105\u017c nie jest znana, ale powszechnie przyjmuje si\u0119 jej autoimmunologiczne pod\u0142o\u017ce. Polega na wieloogniskowym uszkodzeniu m\u00f3zgu i rdzenia kr\u0119gowego. Aktywno\u015b\u0107 choroby i tempo narastania niesprawno\u015bci s\u0105 r\u00f3\u017cne u poszczeg\u00f3lnych pacjent\u00f3w, jednak ich stan neurologiczny systematycznie si\u0119 pogarsza. Jest to choroba wyniszczaj\u0105ca organizm zar\u00f3wno pod wzgl\u0119dem fizycznym, jak i psychicznym. Jednym z najskuteczniej hamuj\u0105cych rozw\u00f3j choroby preparat\u00f3w jest kladrybina. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"Belka\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Soon multiple sclerosis patients will have access to cheaper and more effective drugs. The cladribine pill technology developed in Poland will bring a real breakthrough to the market, increasing access to effective treatment. <\/p>\n","protected":false},"author":140,"featured_media":62967,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"none","_seopress_titles_title":"A Polish \"game changer\" in the treatment of multiple sclerosis","_seopress_titles_desc":"Soon multiple sclerosis patients will have access to cheaper and more effective drugs. The cladribine pill technology developed in Poland will bring a real breakthrough to the market, increasing access to effective treatment. ","_seopress_robots_index":"","inline_featured_image":false,"footnotes":""},"categories":[226,254],"tags":[],"class_list":["post-63600","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en","category-technologies"],"acf":{"czas_czytania":"3"},"publishpress_future_action":{"enabled":false,"date":"2026-04-22 05:38:31","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/posts\/63600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/users\/140"}],"replies":[{"embeddable":true,"href":"https:\/\/lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/comments?post=63600"}],"version-history":[{"count":1,"href":"https:\/\/lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/posts\/63600\/revisions"}],"predecessor-version":[{"id":63601,"href":"https:\/\/lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/posts\/63600\/revisions\/63601"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/media\/62967"}],"wp:attachment":[{"href":"https:\/\/lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/media?parent=63600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/categories?post=63600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/tags?post=63600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}